Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

among other eye conditions (marketed as Eylea), and again in August 2012 to treat metastatic colorectal cancer (marketed as Zaltrap). Both were formed in partnership with Sanofi (SNY), which was ...

The company’s products include EYLEA injection to treat wet age-related ... inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic ...

Regeneron prioritizes returning capital to shareholders. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug, Zaltrap, for use in combination with a folinic acid, fluorouracil and iriontecan (FOLFIRI) chemotherapy ...

The company has successfully developed several blockbuster medicines, including Eylea and Eylea HD for retinal diseases (such as wet age-related macular degeneration, diabetic macular edema ...

The Business Research Company's Eylea HD Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of ...